XML 49 R40.htm IDEA: XBRL DOCUMENT v3.23.3
Research Collaboration and Exclusive License Agreement - Additional Information (Detail)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
Target
Sep. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
Research And Development Arrangement Contract To Perform For Others [Line Items]          
Deferred revenue current $ 3,648   $ 3,648   $ 5,406
Accounts receivable balance outstanding 0   $ 0   $ 0
Merck Agreement          
Research And Development Arrangement Contract To Perform For Others [Line Items]          
Number of collaboration targets | Target     2    
Non-refundable and non-creditable upfront fee     $ 8,000    
Payable upon selection of second collaboration target 8,000   8,000    
Milestone payments     285,000    
Revenue recognized 2,500 $ 1,800 5,600 $ 5,800  
Deferred revenue current $ 3,600   3,600    
Merck Agreement | Maximum          
Research And Development Arrangement Contract To Perform For Others [Line Items]          
Milestone payments per collaboration target     142,500    
Milestone payments upon successful completion of certain commercial milestones     $ 350,000